The Oncotype DX Test Helps You Choose the Best Prostate Cancer Treatment for You

The Oncotype DX prostate cancer test is intended to be used for men recently diagnosed with early-stage prostate cancer. The test looks at the activity of certain genes in your tumor in order to provide personalized information about how aggressive your cancer is. All cancers are not the same. Your prostate cancer may be less aggressive or more favorable than what you would expect based on standard tests like Gleason Score or PSA alone. The information provided by the Oncotype DX prostate cancer test can help you and your doctor determine the most appropriate treatment options for you based on the biology of your individual cancer.  

The Oncotype DX test is performed on the tissue sample previously obtained from your most recent biopsy, and gives you an individualized result called a Genomic Prostate Score (GPS).The GPS has been shown to predict the likelihood, or the odds , that a patient’s prostate cancer will grow and spread.1   

A quick look at how Genomic Health's new Oncotype DX prostate cancer test works to help physicians and their patients choose the most appropriate treatment, enabling more men with low-risk disease to be spared unnecessary treatment and life-altering side effects such as incontinence and impotence. Play Video

Traditionally, doctors have used prostate cancer characteristics such as tumor stage, PSA level and Gleason score to estimate the aggressiveness of prostate cancer and to help guide treatment decisions. These characteristics are helpful but cannot fully determine whether you have low-risk prostate cancer that can be managed with active surveillance, or whether you have aggressive prostate cancer that should be treated immediately with surgery or radiation therapy. The additional information provided by the Oncotype DX prostate cancer test can help you and your doctor decide if active surveillance or invasive treatment is right for you.  

1 Cooperberg et al, AUA 2013, Abstract XX